Dr Reddy's warns Trump's 200% pharma tariffs could spike medicine costs for Americans

The US government is planning steep tariffs on imported generic medicines, with duties potentially reaching 200% over the coming years. Indian pharmaceutical giant Dr Reddy's Laboratories has cautioned that American consumers are likely to face significantly higher medicine prices as a result. The company considers relocating its manufacturing operations to the United States impractical at this stage. India stands to be heavily affected by these measures, given its position as a major supplier of generic drugs to the US market.